H.C. Wainwright raised the firm’s price target on Arvinas (ARVN) to $24 from $18 and keeps a Buy rating on the shares. The firm sees a path forward for vepdegestrant. It cites the company’s pipeline development and progress fort the target increase.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARVN:
- Arvinas price target lowered to $16 from $19 at Wells Fargo
- Arvinas Holding Company: Strong Cash Position and Promising Pipeline Justify Buy Rating
- Arvinas Reports Q2 2025 Financials and Drug Developments
- Arvinas Earnings Call: Balancing Progress and Challenges
- Arvinas Holding Company: Hold Rating Amid Modest Data and Strategic Uncertainties